313 related articles for article (PubMed ID: 26105011)
1. Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness.
Kesselheim AS; Gagne JJ
Drug Saf; 2015 Oct; 38(10):849-53. PubMed ID: 26105011
[TBL] [Abstract][Full Text] [Related]
2. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
Kesselheim AS; Polinski JM; Fulchino LA; Isaman DL; Gagne JJ
Drugs; 2015 Apr; 75(6):633-50. PubMed ID: 25822610
[TBL] [Abstract][Full Text] [Related]
3. Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence.
Gagne JJ; Polinski JM; Jiang W; Dutcher SK; Xie J; Lii J; Fulchino LA; Kesselheim AS
Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):944-52. PubMed ID: 27102378
[TBL] [Abstract][Full Text] [Related]
4. Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence.
Gagne JJ; Polinski JM; Jiang W; Dutcher SK; Xie J; Lii J; Fulchino LA; Kesselheim AS
Drugs; 2017 Mar; 77(4):427-433. PubMed ID: 28181177
[TBL] [Abstract][Full Text] [Related]
5. Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval.
Kesselheim AS; Eddings W; Raj T; Campbell EG; Franklin JM; Ross KM; Fulchino LA; Avorn J; Gagne JJ
PLoS One; 2016; 11(10):e0163339. PubMed ID: 27768700
[TBL] [Abstract][Full Text] [Related]
6. What makes a generic medication generic?
Howland RH
J Psychosoc Nurs Ment Health Serv; 2009 Dec; 47(12):17-20. PubMed ID: 20000278
[TBL] [Abstract][Full Text] [Related]
7. Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process.
Kesselheim AS; Gagne JJ; Franklin JM; Eddings W; Fulchino LA; Campbell EG
Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):694-701. PubMed ID: 28370652
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the bioavailability and bioequivalence of generic medications.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2010 Jan; 48(1):13-6. PubMed ID: 20102127
[TBL] [Abstract][Full Text] [Related]
9. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
10. Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey.
Oner ZG; Michel SLJ; Polli JE
Ann N Y Acad Sci; 2017 Nov; 1407(1):26-38. PubMed ID: 29090833
[TBL] [Abstract][Full Text] [Related]
11. Scientific considerations for generic synthetic salmon calcitonin nasal spray products.
Lee SL; Yu LX; Cai B; Johnsons GR; Rosenberg AS; Cherney BW; Guo W; Raw AS
AAPS J; 2011 Mar; 13(1):14-9. PubMed ID: 21052882
[TBL] [Abstract][Full Text] [Related]
12. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.
Borgheini G
Clin Ther; 2003 Jun; 25(6):1578-92. PubMed ID: 12860486
[TBL] [Abstract][Full Text] [Related]
13. How Does the Food and Drug Administration Approve Topical Generic Drugs Applied to the Skin?
Ghosh P; Raney SG; Luke MC
Dermatol Clin; 2022 Jul; 40(3):279-287. PubMed ID: 35750411
[TBL] [Abstract][Full Text] [Related]
14. United States Food and Drug Administration requirements for approval of generic drug products.
Meyer MC
J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
[TBL] [Abstract][Full Text] [Related]
15. Drug Information Association Pharmacovigilance and Risk Management Strategies 2017: Overview of the Generic Drug Program and Surveillance.
Chazin HD; Peters JR; Catterson DM; Osterhout JL; Forsyth LM; Lee JE; Kim EK; Feibus KB
Ther Innov Regul Sci; 2019 Mar; 53(2):249-253. PubMed ID: 29742934
[TBL] [Abstract][Full Text] [Related]
16. Generic drug product equivalence: current status.
Meyer MC
Am J Manag Care; 1998 Aug; 4(8):1183-9; quiz 1190-2. PubMed ID: 10182892
[TBL] [Abstract][Full Text] [Related]
17. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
18. Scientific considerations in the review and approval of generic enoxaparin in the United States.
Lee S; Raw A; Yu L; Lionberger R; Ya N; Verthelyi D; Rosenberg A; Kozlowski S; Webber K; Woodcock J
Nat Biotechnol; 2013 Mar; 31(3):220-6. PubMed ID: 23471071
[TBL] [Abstract][Full Text] [Related]
19. Generic drugs in dermatology: part II.
Payette M; Grant-Kels JM
J Am Acad Dermatol; 2012 Mar; 66(3):353.e1-15; quiz 367-8. PubMed ID: 22342022
[TBL] [Abstract][Full Text] [Related]
20. A generic drug primer: regulatory aspects and scientific concepts.
Henderson JD; White GL
Mil Med; 1998 Apr; 163(4):193-7. PubMed ID: 9575760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
